Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01461538 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2 study of Acute Myeloid Leukemia and Solid Tumors, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT01461538 is a Phase 2 study of Acute Myeloid Leukemia and Solid Tumors that has completed, run by Seagen. The registered enrollment target is 84 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT01461538, a Phase 2 study of Acute Myeloid Leukemia and Solid Tumors, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
Conditions Studied
Interventions
- DRUG brentuximab vedotin
Study Locations (20)
Texas
- Texas Oncology - Bedford - Bedford
- Texas Oncology - Medical City Dallas - Dallas
- Texas Oncology - Dallas Presbyterian - Dallas
- Texas Oncology Denton South - Denton
- Texas Oncology - Fort Worth 12th Avenue - Fort Worth
- MD Anderson Cancer Center / University of Texas - Houston
California
- City of Hope - Duarte
- PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists - Oxnard
Florida
- Mayo Clinic Cancer Center - Jacksonville
- Ocala Oncology Center - Ocala
Oregon
- Willamette Valley Cancer and Research / USOR - Eugene
- Northwest Cancer Specialists, P.C. - Tulatin
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01461538
The ClinicalTrials.gov registry entry for NCT01461538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (28% lower). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which brentuximab vedotin is the first listed.
NCT01461538 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01461538 about?
NCT01461538 is a clinical study titled "Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies". This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
What is the current status of trial NCT01461538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2011-10. Estimated completion is 2014-12.
What conditions does trial NCT01461538 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Solid Tumors, Acute Lymphoid Leukemia, Anemia, Refractory, With Excess of Blasts.
What interventions are being tested in trial NCT01461538?
The interventions under investigation include: brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT01461538?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01461538 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.